Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Teva Pharmaceutical Industries Limited < Previous 1 2 3 4 5 Next > Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM April 19, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022 April 04, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting April 01, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims March 30, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims March 21, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Fourth Quarter and Full Year 2021 Financial Results February 09, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims February 07, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Research Finds COVID Pandemic Worsened Health Equity Gap February 01, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022 January 18, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference January 04, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Statement Following New York Jury Ruling in Opioids Trial December 30, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S. December 22, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S. December 01, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement November 10, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes November 02, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids November 01, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia October 30, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024 October 27, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes October 27, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Third Quarter 2021 Financial Results October 27, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate October 26, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021 October 21, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021 October 01, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN September 30, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD September 30, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims September 28, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant September 08, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache... August 30, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia August 20, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis July 28, 2021 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.